Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT03245736 Completed - Prostate Cancer Clinical Trials

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Start date: August 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.

NCT ID: NCT03238066 Recruiting - Prostate Cancer Clinical Trials

Salvage Brachytherapy and Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following Radiation Therapy

Prostata-BT-HT
Start date: April 2015
Phase: N/A
Study type: Interventional

Salvage brachytherapy in combination with interstitial hyperthermia for locally recurrent prostate carcinoma following external beam radiation therapy.

NCT ID: NCT03237026 Recruiting - Prostate Cancer Clinical Trials

Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients

Start date: October 11, 2017
Phase:
Study type: Observational

The study aims to identify potential urine marker metabolites as predictive or prognostic markers for treatment outcomes in patients with prostate cancer.

NCT ID: NCT03235557 Completed - Prostate Cancer Clinical Trials

CyberKnife for Prostate Cancer Patients Aged 70 y or More

ProRobot
Start date: October 2014
Phase:
Study type: Observational [Patient Registry]

Robotic Stereotactic Radiation treatment of prostatic adenocarcinoma of the elderly. Inclusion criteria : T1-T3b, MRI pelvic nodes negative, M0, any Gleason Score, PSA (Prostate Specific Antigen) <30ng/ml. Dose : 36.25 Gy in 5 fractions, in 10 days, considering CAPRA Scores≤5 AND 37.5 Gy in 5 fractions, in 10 days, considering CAPRA Scores>5. Primary objective : acute and late toxicity evaluation at 36 months. Secondary objectives : PSA and MRI response.

NCT ID: NCT03233672 Completed - Prostate Cancer Clinical Trials

Hypo-fractionated Postoperative IMRT in Prostate Cancer

Start date: September 18, 2007
Phase: N/A
Study type: Interventional

To report the outcome of hypo-fractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using IMRT-SIB. 124 patients with PCa at high risk of relapse after RP or diagnosis of biochemical relapse were included. Patients received 62.5 Gy to the prostate bed (PB) and 45 Gy to pelvis nodes in 25 fractions. Androgen suppressive therapy was prescribed based on NCCN risk categories. Median follow-up was 30 months.

NCT ID: NCT03232411 Completed - Prostate Cancer Clinical Trials

Biobank for African American Prostate Cancer Research in Florida

Start date: March 22, 2017
Phase:
Study type: Observational

The purposes of this study are: a) to develop a statewide Biobank for prostate cancer among men of African Ancestry in Florida and; b) to examine whether smoking increases the aggressiveness of prostate cancer using several biological approaches. Investigators plan to contact African American prostate cancer patients regarding participation. This project has 3 main components. Eligible patients may choose to participate in any or all parts of the study: Questionnaires; Saliva Samples; Tumor Tissue.

NCT ID: NCT03232164 Recruiting - Prostate Cancer Clinical Trials

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

Start date: February 2, 2017
Phase: Early Phase 1
Study type: Interventional

The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a biomarker may be useful to differentiate indolent from aggressive prostate cancer phenotypes allowing for selection of an appropriate risk adaptive therapy.

NCT ID: NCT03232125 Completed - Prostate Cancer Clinical Trials

Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Intraperitoneal insufflation of carbon dioxide may affect the sympathetic activity that leads to changes in ventricular re-polarization. This in turn can result in changes of heart rate-corrected QT (QTc) interval. Ramosetron is a 5-hydroxytryptamine three receptor antagonist and widely used anti-emetics. However, QTc interval prolongation has been observed in a number of patients after administration of 5-HT3 receptor antagonists. The aim of this study is to evaluate the effects of ramosetron on QTc interval and possible cardiovascular adverse effects during robot-assisted laparoscopic prostatectomy with steep Trendelenburg position.

NCT ID: NCT03228810 Completed - Prostate Cancer Clinical Trials

Genetic Biomarker Discovery for Metastatic Prostate Cancer

Start date: May 2, 2017
Phase:
Study type: Observational

Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. If patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery. Subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur.

NCT ID: NCT03228108 Completed - Prostate Cancer Clinical Trials

Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.

pro-SWAP
Start date: April 3, 2018
Phase: Phase 4
Study type: Interventional

This study aims to assess the effectiveness and cost-effectiveness of rectal swab culture-guided antimicrobial prophylaxis to reduce infectious complications after transrectal prostate biopsy. Half of participants will receive routine empirical prophylaxis with oral ciprofloxacin (control group), while the other half will receive rectal culture-guided oral antibiotic prophylaxis (intervention group). In the intervention group, men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prophylaxis, comparable to the control group. In case of ciprofloxacin-resistant bacteria an alternative oral antibiotic based on the culture results will be prescribed (trimethoprim/sulfamethoxazole, fosfomycin or pivmecillinam/augmentin). The investigators hypothesise that the targeted prophylaxis group (intervention group) will have a lower rate of post-biopsy infectious complications compared to the control group.